not enough for the two bash turding this stock, 200m passed in 2012, the FDA grants a Rare Pediatric Disease Designation for serious and life threatening diseases that primarily affect children. If a new drug application for MC1 for patients with PNPO defficiency ia approved, the company may be eligible to receive a priority review voucher from the FDA. This voucher will cover the cost to research the drug, test the drug, market the drug and can be upwards of 100 to 200 million US dollars.
Otherwise pharma would not try to solve these rare conditions for children.